A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer (eMonarcHER)
The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+).
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have confirmed hormone receptor positive (HR+), human epidermal receptor 2 positive (HER2+) breast cancer
Participants must have had surgery for this breast cancer
Participants must have had chemotherapy and therapy targeted for HER2+ breast cancer
Female participant of child-bearing potential must agree to use highly effective birth control methods
Participants must be able to swallow oral medications
Participants Must Not:
Female participant must not be pregnant or breastfeeding
Participants must not have breast cancer that has spread to another part(s) of the body
Participants must not have received an experimental treatment in a clinical trial within the last 30 days
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo